Bispecific CAR-T cell targeting CD19 and CD22 and application thereof

By designing chimeric antigen receptors targeting CD19 and CD22, bispecific CAR-T cells were constructed, solving the problem of recurrence after CD19 CAR-T cells treatment, and achieving continuous killing and immunosuppression of tumor cells. The survival of mice was significantly extended.

CN119039452APending Publication Date: 2024-11-29PERSONGEN BIOTHERAPEUTICS (SUZHOU) CO LTD +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202310616958.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The high rate of recurrence after CD19 CAR-T cell treatment is mainly due to two major reasons: antigen-positive recurrence and antigen-negative recurrence. The existing bispecific CAR-T cells have limited efficacy and need to develop the ability to target multiple antigen targets at the same time. chimeric antigen receptor.

Method used

A chimeric antigen receptor (CAR) was designed with bispecific targeting CD19 and CD22, with structures including S-AB1-L-AB2-H-TM-C-CD3ζ, and AB1 and AB2 targeting CD19, respectively The antigen-binding domain of CD22 was optimized through different linking peptide and signal peptide sequences to construct new CAR-T cells.

Benefits of technology

It realizes the continuous killing ability of tumor cells in vitro and in vivo, improves cytokine secretion, reduces the secretion of the immunosuppressive factor IL-10, significantly prolongs the survival of mice, and effectively controls it in simulated CD19-negative recurrence situations. Tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004254207280000211
    Figure BDA0004254207280000211
  • Figure BDA0004254207280000221
    Figure BDA0004254207280000221
  • Figure BDA0004254207280000231
    Figure BDA0004254207280000231
Patent Text Reader

Abstract

The invention provides a bispecific CAR-T (Chimeric Antigen Receptor-T) cell capable of simultaneously targeting CD19 or CD22 positive tumor cells. T cells expressing the CAR show cytotoxicity and cytokine secretion superior to those of single-target CAR-T cells in an in-vitro experiment, meanwhile, a better in-vivo anti-tumor effect is shown in a mouse experiment, and a new strategy is provided for solving the limitation that the curative effect is limited or relapse exists when the single-target CAR-T is used for treating tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biopharmaceuticals, and in particular, to bispecific CAR-T cells targeting CD19 and CD22 and applications thereof. Background Art

[0002] CD19 CAR-T cell therapy has greatly improved the treatment of patients with B-cell malignancies. However, most patients still experience disease progression due to tumor recurrence after CD19 CAR-T treatment. There are many reasons for recurrence after CD19 CAR-T treatment, which can be divided into two categories: antigen-negative recurrence and antigen-positive recurrence. Antigen-positive recurrence is mainly caused by poor persistence of CAR-T cells in the body or the immunosuppressive microenvironment in the human body. The expression of immunosuppressive factors, such as PD-L1, IDO, IL-10, etc., or the exhaustion or inability of CAR-T cells to expand in the body, may lead to tumor cell antigen-positive recurrence in patients after CAR-T cell treatment. Antigen-negative recurrence, that is, the loss of CD19 antigen epitopes, is also an important cause of recurrence after CAR-T cell treatment. Common causes such as the loss of chromosome fragments, transcription factor loss or exon mutations may lead to downregulation or non-expression of CD19 antigen expression, resulting in recurrence of the patient's disease. It has been reported that the detection of tumor cells in patients who relapsed after CD19 CAR-T treatment showed that CD22 expression was positive.

[0003] The high relapse rate after CD19 CAR-T cell therapy requires further design and development of new treatments. Adding a new therapeutic target has become a consensus among many researchers. At present, there have been many reports on the development of bispecific CAR-T, and the actual efficacy of some studies is limited. There are many possibilities for the exploration of dual-target CAR-T cells, and slight changes in the structure may also have completely different effects. A deeper understanding and research of the structure of dual-target CAR-T is also needed in order to truly achieve the desired effect.

[0004] Therefore, there is a need in the art to develop chimeric antigen receptors that can simultaneously target multiple antigen targets. Summary of the invention

[0005] The object of the present invention is to provide a bispecific CAR targeting CD19 and CD22.

[0006] In a first aspect of the present invention, a chimeric antigen receptor (CAR) is provided, wherein the chimeric antigen receptor has a structure shown in the following formula I from N-terminus to C-terminus:

[0007] S-AB1-L-AB2-H-TM-C-CD3ζ(I)

[0008] In the formula,

[0009] Each "-" is independently a connecting peptide or a peptide bond;

[0010] S is an optional signal peptide sequence;

[0011] L is the connector;

[0012] H is an optional hinge region;

[0013] TM is the transmembrane domain;

[0014] C is a co-stimulatory signal molecule;

[0015] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ;

[0016] One of AB1 and AB2 is an antigen-binding domain targeting CD19, and the other is an antigen-binding domain targeting CD22.

[0017] In another preferred embodiment, the AB1 is an antigen binding domain targeting CD22, and the AB2 is an antigen binding domain targeting CD19; or

[0018] AB2 is an antigen binding domain targeting CD22, and AB1 is an antigen binding domain targeting CD19.

[0019] In another preferred embodiment, the forms of AB1 and AB2 are independently selected from the following groups: Fab fragment, Fab' fragment, F(ab')2 fragment, single-chain antibody variable region fragment (scFv), or nanobody, or a combination thereof.

[0020] In another preferred embodiment, the antigen binding domain targeting CD22 is a nanobody, and the antigen binding domain targeting CD19 is a scFv.

[0021] In another preferred embodiment, AB1 and / or AB2 are each independently a murine antibody, a human antibody, a humanized antibody or a chimeric antibody.

[0022] In another preferred embodiment, AB1 is a nanobody targeting CD22; AB2 is a scFv targeting CD19.

[0023] In another preferred embodiment, the Nanobody targeting CD22 has the following complementary determining region CDR:

[0024] CDR1 shown in SEQ ID NO: 1;

[0025] CDR2 shown in SEQ ID NO:2; and

[0026] CDR3 shown in SEQ ID NO:3.

[0027] In another preferred example, the amino acid sequence of the Nanobody targeting CD22 is shown in SEQ ID NO:4.

[0028] In another preferred embodiment, the scFv targeting CD19 has a heavy chain variable region and a light chain variable region, and the heavy chain variable region has the following complementary determining region CDR:

[0029] HCDR1 shown in SEQ ID NO:5;

[0030] HCDR2 shown in SEQ ID NO:6; and

[0031] HCDR3 shown in SEQ ID NO:7;

[0032] The light chain variable region has the following complementarity determining regions CDR:

[0033] LCDR1 shown in SEQ ID NO:8;

[0034] LCDR2 shown in SEQ ID NO:9;

[0035] LCDR3 shown in SEQ ID NO:10.

[0036] In another preferred embodiment, the scFv targeting CD19 has a heavy chain variable region as shown in SEQ ID NO: 11 and / or a light chain variable region as shown in SEQ ID NO: 12.

[0037] In another preferred embodiment, the structure of the scFv targeting CD19 is shown in Formula A or Formula B below:

[0038] VH-VL(A); VL-VH(B)

[0039] In the formula, VH is the heavy chain variable region of anti-CD19; VL is the light chain variable region of anti-CD19; and “-” is a connecting peptide or peptide bond.

[0040] In another preferred embodiment, the VH and VL are connected via a linker (or connecting peptide), and the linker (or connecting peptide) is 1-4 consecutive sequences represented by G4S, preferably 2-4, and more preferably 3-4.

[0041] In another preferred embodiment, the scFv targeting CD19 has an amino acid sequence as shown in SEQ ID NO: 14 or 15.

[0042] In another preferred embodiment, the AB1 is a nanobody targeting CD22, the AB2 is a scFv targeting CD19, and the structure of the scFv targeting CD19 is as shown in Formula A; or

[0043] AB2 is a nanobody targeting CD22, AB1 is a scFv targeting CD19, and the structure of the scFv targeting CD19 is shown in Formula B.

[0044] In another preferred embodiment, the joint L is a rigid joint.

[0045] In another preferred embodiment, the linker L sequence is as shown in (EAAAK)n, wherein n is 2-6, preferably 2-4, and more preferably 3-4.

[0046] In another preferred embodiment, the linker L sequence is shown as SEQ ID NO:22.

[0047] In another preferred embodiment, the S is a signal peptide selected from the following group: CD8, CD28, GM-CSF, CD4, CD137, or a combination thereof.

[0048] In another preferred embodiment, the S comprises the amino acid sequence shown in SEQ ID NO:16.

[0049] In another preferred embodiment, the H is derived from IgG 4Fc.

[0050] In another preferred embodiment, the H comprises the amino acid sequence shown in SEQ ID NO:17.

[0051] In another preferred embodiment, the TM is a transmembrane region of a protein selected from the following group: ICOS, CD8, CD28, CD3epsilon, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or a combination thereof.

[0052] In another preferred embodiment, the TM includes a transmembrane region derived from ICOS.

[0053] In another preferred embodiment, C is a co-stimulatory signal molecule of a protein selected from the following group: OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, TLR2, or a combination thereof.

[0054] In another preferred embodiment, the C includes costimulatory signal molecules derived from ICOS and 4-1BB.

[0055] In another preferred example, the CAR comprises the amino acid sequences shown in SEQ ID NOs: 18 and 19.

[0056] In another preferred embodiment, the CD3ζ comprises the amino acid sequence shown in SEQ ID NO:20.

[0057] In another preferred example, the CAR amino acid sequence is shown in SEQ ID NO: 23, 24, 25 or 26.

[0058] In a second aspect of the present invention, a nucleic acid molecule is provided, wherein the nucleic acid molecule encodes the chimeric antigen receptor (CAR) as described in the first aspect of the present invention.

[0059] In the third aspect of the present invention, a vector is provided, wherein the vector contains the nucleic acid molecule as described in the second aspect of the present invention.

[0060] In another preferred embodiment, the vector is selected from the following group: DNA, RNA, plasmid, lentiviral vector, adenoviral vector, adeno-associated viral vector (AAV), retroviral vector, transposon, or a combination thereof.

[0061] In another preferred embodiment, the vector is selected from the following group: plasmid, viral vector.

[0062] In another preferred embodiment, the vector is in the form of a virus particle.

[0063] In another preferred embodiment, the vector is a lentiviral vector.

[0064] In the fourth aspect of the present invention, a host cell is provided, wherein the host cell contains the vector as described in the third aspect of the present invention or a chromosome in which an exogenous nucleic acid molecule as described in the second aspect of the present invention is integrated or expresses the CAR as described in the first aspect of the present invention.

[0065] In another preferred embodiment, the host cells include eukaryotic cells and prokaryotic cells.

[0066] In another preferred embodiment, the host cell includes Escherichia coli.

[0067] In the fifth aspect of the present invention, an engineered immune cell is provided, wherein the immune cell expresses the CAR as described in the first aspect of the present invention.

[0068] In another preferred embodiment, the cell is an isolated cell, and / or the cell is a genetically engineered cell.

[0069] In another preferred embodiment, the immune cells are from humans or non-human mammals (such as mice).

[0070] In another preferred embodiment, the cells include T cells and NK cells.

[0071] In another preferred embodiment, the cell is a CAR-T cell or a CAR-NK cell, preferably a CAR-T cell.

[0072] In another preferred embodiment, CAR and cell suicide elements are co-expressed in the immune cells.

[0073] In the sixth aspect of the present invention, a preparation is provided, which contains the chimeric antigen receptor as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, or the immune cell as described in the fifth aspect of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient.

[0074] In another preferred embodiment, the preparation is a liquid preparation.

[0075] In another preferred embodiment, the preparation is in the form of an injection.

[0076] In another preferred embodiment, the concentration of the CAR-T cells in the preparation is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.

[0077] In another preferred embodiment, the pharmaceutical composition further comprises a second anti-tumor active ingredient, preferably a second antibody or a chemotherapeutic agent.

[0078] In another preferred embodiment, the chemotherapeutic agent is selected from the following group: docetaxel, carboplatin, or a combination thereof.

[0079] In the seventh aspect of the present invention, there is provided a use of the chimeric antigen receptor as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, or the immune cell as described in the fifth aspect of the present invention, or the preparation as described in the sixth aspect of the present invention for preparing a drug or preparation for preventing and / or treating cancer or tumors.

[0080] In another preferred embodiment, the tumor is selected from the following group: a blood tumor, a solid tumor, or a combination thereof.

[0081] In another preferred embodiment, the blood tumor is selected from the group consisting of acute myeloid leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), or a combination thereof.

[0082] In another preferred embodiment, the solid tumor is selected from the following group: gastric cancer, gastric cancer peritoneal metastasis, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer, or a combination thereof.

[0083] In another preferred embodiment, the tumor is a CD19 and / or CD22 positive tumor.

[0084] In another preferred embodiment, the CD19 and / or CD22 positive tumors include B cell related tumors.

[0085] In another preferred embodiment, the tumor is B-acute lymphocytic leukemia (B-ALL), B-cell lymphoma, or a combination thereof.

[0086] In an eighth aspect of the present invention, a method for preparing the engineered immune cells according to the fifth aspect of the present invention is provided, the method comprising the following steps:

[0087] (a) providing immune cells to be modified; and

[0088] (b) transducing the nucleic acid molecule described in the second aspect of the present invention or the vector described in the third aspect of the present invention into the immune cell, thereby obtaining the engineered immune cell.

[0089] In another preferred embodiment, the engineered immune cells are CAR-T cells or CAR-NK cells.

[0090] In another preferred embodiment, the method further comprises the step of testing the function and effectiveness of the obtained engineered immune cells.

[0091] In a ninth aspect of the present invention, a method for inhibiting tumor cells in vitro is provided, comprising the steps of:

[0092] The tumor cells are contacted with the vector according to the third aspect of the present invention, the immune cell according to the fifth aspect of the present invention, or the preparation according to the sixth aspect of the present invention, thereby inhibiting the tumor cells.

[0093] In another preferred embodiment, the tumor cells are CD19 and / or CD22 positive cells.

[0094] In another preferred embodiment, the cells are Raji cells.

[0095] In the tenth aspect of the present invention, a method for treating a disease is provided, comprising administering an appropriate amount of the vector as described in the third aspect of the present invention, the immune cell as described in the fifth aspect of the present invention, or the preparation as described in the sixth aspect of the present invention to a subject in need of treatment.

[0096] In another preferred embodiment, the disease is cancer or tumor.

[0097] In another preferred embodiment, the tumor includes B-acute lymphocytic leukemia (B-ALL), B-cell lymphoma, or a combination thereof.

[0098] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0099] Figure 1 shows the structure and functional verification of CD22 CAR-T cells constructed based on the nanoantibody sequence. Figure 1A Schematic diagram of the CD22 CAR structure. Figure 1B and Figure 1C The results of flow cytometric analysis of tumor cell apoptosis after CD22 CAR-T cells were incubated with Raji (CD22+) and K562 (CD22-) at different effector-target ratios for 24 hours. *P<0.05; P<0.01; ***P<0.001 (two-tailed paired t test). Figure 1D After CD22 CAR-T cells were co-cultured with Raji cells for 24 hours, the culture supernatant was collected and the production of cytokines was detected. Figure 1E The process diagram is shown in Figure 1. On day 0, 1×10 6 Raji-luciferase cells were injected into the tail vein of NSG mice, and 1×10 7 CD22CAR-T cells. Figure 1F The statistical results of mouse body weight. Figure 1G Kaplan-Meier survival analysis of CD22 CAR-T-treated mice bearing Raji-luciferase cells. Figure 1H Bioluminescence images of mice in the CAR-T group and UT group at different time points. Fig. 1I The firefly luciferase assay results of tumor cell apoptosis after CAR-T cells were co-incubated with Raji-luciferase cells for 24 hours. Figure 1JThe results of cytokine secretion after CAR-T cells were co-incubated with Raji-luciferase cells for 24 hours.

[0100] FIG2 shows the structural design and optimization of the bispecific CAR vector. Figure 2A Schematic diagram of four bispecific CAR structures. Figure 2B The results of flow cytometry detection of CAR-T cell transfection efficiency. Figure 2C The fluorescence detection results of the cytotoxicity of different CAR-T cells to Raji-luciferase cells at three effector-target ratios. Figure 2D The results of cytokine detection in the supernatant after co-incubation of different CAR-T cells with Raji-luciferase cells. Figure 2E , Figure 2F and Figure 2G These are the flow cytometry results of tumor cell apoptosis after CAR-T cells were co-incubated with Raji, Nalm6, K562 (CD19+), K562 (CD22+) and K562 (CD19+CD22+) cells at different effector-target ratios for 24 hours.

[0101] Figure 3 shows that bispecific CAR-T cells have good sustained killing ability against target cells in vitro. Figure 3A and Figure 3B The results of flow cytometry detection of CD69 / CD25 molecule expression on the surface of CAR-T cells after different CAR-T cells were co-incubated with K562 (CD19+), K562 (CD22+), and Raji (CD19+CD22+) cells for 24 hours. Figure 3C To convert 2*10 6 CAR-T cells were inoculated in the detection wells, and Raji cells were added every day at designated time points on days 0, 1, 2, and 3 at an E:T ratio of 1:1. Cells were collected daily on days 0, 1, 2, and 3 to detect tumor cell apoptosis. Figure 3D To detect the expression levels of cytokines in the culture medium supernatant during the continuous killing process. Figure 3E The results of flow cytometry detection of CAR-T cell memory phenotype differentiation during sustained killing. Figure 3F Flow cytometric detection of T cell exhaustion markers after CAR-T cells continued killing for four days.

[0102] FIG4 shows that Bis-C CAR-T cells have excellent anti-tumor effects in vivo. Figure 4A The results of flow cytometry detection of CD19 and CD22 expression in K562 cells containing different ratios of CD19 and CD22 antigens obtained by mixing K562 (CD19+) and K562 (CD22+) cells in different ratios. Figure 4B The flow cytometry results of tumor cell apoptosis after CAR-T cells were co-incubated with five types of K562 cells at an effector-target ratio of E:T=20:1 for 24 hours. Figure 4C Statistical results for continuous monitoring of mouse body weight. Figure 4D Kaplan-Meier survival analysis of CAR-T-treated Raji-luciferase cell-bearing mice. Figure 4E Tumor burden detection of mice in each group. Figure 4F Figure 2 is a flow chart, where on day 0, 100% WT-Raji-luciferase, 100% CD19KO-Raji-luciferase, and 50% WT-Raji-luciferase + 50% CD19KO-Raji-luciferase cells were added at the same dose (1*10 6 ) were injected into the tail vein of NSG mice. On the 4th day, 1*10 7 CD19 CAR-T or Bis-CCAR-T cells were injected into tumor-bearing mice through the tail vein. Figure 4G Bioluminescence images of each group of mice at designated time points after tumor loading.

[0103] Figure 5 These are the detection results of cytokine release in the supernatant after CAR-T cells were co-cultured with K562 (CD19+), K562 (CD22+), and K562 (CD19+CD22+). DETAILED DESCRIPTION

[0104] After extensive and in-depth research, the inventors selected two connecting peptides and designed a total of four different CD19 / CD22 CAR structures. By comparing these structures, a new type of bispecific CAR-T cell that can simultaneously target CD19 or CD22 positive tumor cells was screened out. The CAR-T cells of the present invention have good performance in sustained killing, cytokine secretion, target antigen specificity, and differentiation of memory phenotypes. T cells expressing the CAR of the present invention showed superior cytotoxicity to single-target CAR-T cells in in vitro experiments, and showed better in vivo anti-tumor effects in mouse experiments. On this basis, the present invention is completed.

[0105] the term

[0106] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.

[0107] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.

[0108] The term "administering" refers to the physical introduction of the product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.

[0109] The term "antibody" (Ab) shall include, but is not limited to, immunoglobulins that specifically bind to an antigen and comprise at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or antigen-binding portions thereof. Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region comprises three constant domains CH1, CH2, and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one constant domain CL. The VH and VL regions can be further subdivided into hypervariable regions called complementary determining regions (CDRs), which are interspersed with more conservative regions called framework regions (FRs). Each VH and VL comprises three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens.

[0110] It should be understood that the amino acid names herein are identified by internationally accepted single-letter English letters, and the corresponding three-letter abbreviations of the amino acid names are: Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P), Ser (S), Thr (T), Trp (W), Tyr (Y), and Val (V).

[0111] Anti-CD19 antibodies

[0112] CD19 is a membrane protein specifically expressed by B cells. Almost all B cell tumor cells express CD19 molecules on their surface, so CD19 is an ideal target for targeted therapy of B cell tumors.

[0113] At present, mouse scFv is still commonly used in the development of CD19 / CD22 CAR-T cells. For example, CD19scFv is mostly a mouse antibody sequence cloned by FMC63. Studies have shown that mouse antibody sequences can induce immunogenic reactions in the human body, accelerate the clearance of CAR-T in the blood, and thus affect the efficacy. Therefore, it is necessary to humanize the mouse CD19 antibody sequence and build it into the dual-target CAR structure.

[0114] In one embodiment of the present invention, the scFv targeting CD19 has a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has the following complementarity determining regions CDR:

[0115] HCDR1 shown in SEQ ID NO:5;

[0116] HCDR2 shown in SEQ ID NO:6; and

[0117] HCDR3 shown in SEQ ID NO:7;

[0118] The light chain variable region has the following complementarity determining regions CDR:

[0119] LCDR1 shown in SEQ ID NO:8;

[0120] LCDR2 shown in SEQ ID NO:9;

[0121] LCDR3 shown in SEQ ID NO:10.

[0122] In one embodiment of the present invention, the scFv targeting CD19 has a heavy chain variable region as shown in SEQ ID NO:11 and / or a light chain variable region as shown in SEQ ID NO:12.

[0123] Anti-CD22 Nanobody

[0124] CD22 is a member of the sialic acid-binding immunoglobulin family. It is mainly expressed intracellularly in the early stages of B cell development, and is transferred to the extracellular space as B cells mature. It is highly expressed in most B cell malignancies. CD22 is a potential anti-tumor target.

[0125] Based on the fact that the development of bispecific CAR may lead to the problem of low transfection efficiency due to its large structure, for the development of CD22 antibody sequence, nanoantibodies with small size and high affinity were selected and applied to the construction of bispecific CAR.

[0126] As used herein, the terms "single domain antibody (VHH)" and "nanobody" have the same meaning, referring to the variable region of the heavy chain of a monoclonal antibody, and constructing a single domain antibody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with complete functions. Usually, an antibody naturally lacking the light chain and heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single domain antibody (VHH) consisting of only one heavy chain variable region.

[0127] In one embodiment of the invention, the Nanobody targeting CD22 has the following complementary determining regions CDR:

[0128] CDR1 shown in SEQ ID NO: 1;

[0129] CDR2 shown in SEQ ID NO:2; and

[0130] CDR3 shown in SEQ ID NO:3.

[0131] In one embodiment of the present invention, the amino acid sequence of the Nanobody targeting CD22 is shown in SEQ ID NO:4.

[0132] Connectors

[0133] As used herein, the terms "connector" and "linker" have the same meaning and refer to any oligopeptide or polypeptide that acts to connect the components of the chimeric antigen receptor together. The connecting peptide can, for example (but not limited to), connect antigen binding fragments targeting different antigens, or connect the transmembrane domain to the extracellular domain or cytoplasmic domain of the polypeptide chain. The linker can include 0-300 amino acids, preferably 2 to 100 amino acids, and most preferably 3 to 50 amino acids.

[0134] The CAR structure has a significant impact on the functional activity of CAR-T cells. Linkers play an important role in connecting two proteins with different structures and functions. According to research on fusion proteins, linkers not only play a simple covalent connection role in fusion proteins, but also the properties of linkers, such as length and amino acid content, are important parameters affecting the properties of fusion proteins. The (EAAAK)3 linker has a large number of hydrogen bonds and can fold into a stable helical conformation. The more helical conformations, the more rigid the structure. The (G4S)4 linker is a flexible and random coil conformation.

[0135] In one embodiment of the present invention, the anti-CD19 domain and the anti-CD22 domain in the CAR of the present invention are connected by a rigid linker, such as an (EAAAK)3 linker.

[0136] Chimeric Antigen Receptor (CAR)

[0137] As used herein, a "chimeric antigen receptor (CAR)" is a fusion protein comprising an extracellular domain capable of binding to an antigen, a transmembrane domain derived from a different polypeptide than the extracellular domain, and at least one intracellular domain. "Chimeric Antigen Receptor (CAR)" is sometimes also referred to as a "chimeric receptor", "T-body" or "chimeric immune receptor (CIR)". An "extracellular domain capable of binding to an antigen" refers to any oligopeptide or polypeptide capable of binding to an antigen. An "intracellular domain" refers to any oligopeptide or polypeptide known to function as a domain that transmits signals to activate or inhibit biological processes within a cell.

[0138] Specifically, the chimeric antigen receptor (CAR) of the present invention includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain includes a target-specific binding element (also referred to as an antigen binding domain). The intracellular domain includes a costimulatory signaling region and a ζ chain portion. The costimulatory signaling region refers to a portion of the intracellular domain including a costimulatory molecule. Costimulatory molecules are cell surface molecules required for the effective response of lymphocytes to antigens, rather than antigen receptors or their ligands.

[0139] A linker may be incorporated between the extracellular domain and the transmembrane domain of the CAR, or between the cytoplasmic domain and the transmembrane domain of the CAR.

[0140] The CAR of the present invention, when expressed in T cells, can recognize antigens based on antigen binding specificity. When it binds to its associated antigen, it affects tumor cells, causing tumor cells not to grow, to be prompted to die or otherwise affected, and causes the patient's tumor load to shrink or eliminate. The antigen binding domain is preferably fused with one or more intracellular domains from a co-stimulatory molecule and a ζ chain. For example, the antigen binding domain is fused with the intracellular domain of a combination of a 4-1BB signaling domain and a CD3ζ signaling domain.

[0141] As used herein, "antigen binding domain" refers to a Fab fragment, Fab' fragment, F(ab')2 fragment, or scFv fragment, or nano antibody fragment, or a combination thereof having antigen binding activity. Fv antibodies contain antibody heavy chain variable regions, light chain variable regions, but no constant region, and are the smallest antibody fragments with all antigen binding sites. Generally, Fv antibodies also include a polypeptide linker between the VH and VL domains, and are capable of forming the structure required for antigen binding. In one embodiment, the antigen binding domain of the present invention may include scFv (single-chain variable fragment), nano antibodies, or a combination thereof. The size of scFv is generally 1 / 6 of a complete antibody. A single-chain antibody is preferably an amino acid chain sequence encoded by a nucleotide chain. Nano antibodies are single-domain antibodies consisting only of a heavy chain variable region. As one embodiment of the present invention, the extracellular binding domain of CAR comprises antibodies that specifically recognize tumor-highly expressed antigens CD19 or CD22, such as anti-CD19 scFv and anti-CD22 nano antibodies.

[0142] In the present invention, the antigen binding domain of the CAR of the present invention also includes its conservative variants, which means that compared with the amino acid sequence of the antigen binding domain of the CAR of the present invention, at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids are replaced by amino acids with similar or similar properties to form a polypeptide.

[0143] In the present invention, the number of added, deleted, modified and / or substituted amino acids is preferably no more than 40% of the total number of amino acids in the initial amino acid sequence, more preferably no more than 35%, more preferably 1-33%, more preferably 5-30%, more preferably 10-25%, more preferably 15-20%.

[0144] In the present invention, the number of amino acids added, deleted, modified and / or substituted is usually 1, 2, 3, 4 or 5, preferably 1-3, more preferably 1-2, and most preferably 1.

[0145] With respect to the hinge region and the transmembrane region (transmembrane domain), the CAR can be designed to include the transmembrane domain fused to the extracellular domain of the CAR.

[0146] Carrier

[0147] The present invention also provides a DNA construct encoding the CAR sequence of the present invention.

[0148] The nucleic acid sequence encoding the desired molecule can be obtained using recombinant methods known in the art, such as, for example, by screening a library from a cell expressing the gene, by obtaining the gene from a known vector comprising the gene, or by directly isolating from cells and tissues comprising the gene using standard techniques. Alternatively, the gene of interest can be produced synthetically.

[0149] The present invention also provides vectors into which the expression cassette of the present invention is inserted. Vectors derived from retroviruses such as lentiviruses are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenes and their proliferation in daughter cells. Lentiviral vectors have advantages over vectors derived from oncogenic retroviruses such as murine leukemia viruses because they can transduce non-proliferating cells, such as hepatocytes. They also have the advantage of low immunogenicity.

[0150] In brief summary, the expression cassette or nucleic acid sequence of the present invention is usually operably connected to a promoter and incorporated into an expression vector. The vector is suitable for replication and integration into eukaryotic cells. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters that can be used to regulate the expression of the desired nucleic acid sequence.

[0151] The expression constructs of the present invention can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Methods of gene delivery are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, 5,589,466, which are incorporated herein by reference in their entirety. In another embodiment, the present invention provides a gene therapy vector.

[0152] The nucleic acid can be cloned into many types of vectors. For example, the nucleic acid can be cloned into such vectors, which include but are not limited to plasmids, phagemids, phage derivatives, animal viruses and cosmids. Specific vectors of interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors.

[0153] Further, expression vector can be provided to cell in the form of viral vector. Viral vector technology is well known in the art and described in, for example, Sambrook et al. (2001, Molecular Cloning: Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals. The virus that can be used as a vector includes but is not limited to retrovirus, adenovirus, adeno-associated virus, herpes virus and slow virus. Generally, suitable vectors are included in at least one organism, which has a replication origin, a promoter sequence, a convenient restriction enzyme site and one or more selectable markers (for example, WO01 / 96584; WO01 / 29058; and U.S. Patent number 6,326,193).

[0154] Many virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject's cells in vivo or in vitro. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In one embodiment, a lentiviral vector is used.

[0155] Additional promoter elements, such as enhancers, can regulate the frequency of transcription initiation. Typically, these are located in the 30-110 bp region upstream of the start site, although recently it has been shown that many promoters also contain functional elements downstream of the start site. The spacing between promoter elements is often flexible so that when an element is inverted or moved relative to another, the promoter function is maintained. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it is shown that individual elements can work cooperatively or independently to start transcription.

[0156] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence operably connected thereto to express at a high level. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr (Epstein-Barr) virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Further, the present invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered to be part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence operably linked to an inducible promoter when such expression is desired, or turn off expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

[0157] In order to evaluate the expression of CAR polypeptides or parts thereof, the expression vector introduced into the cell may also include any one or both of a selectable marker gene or a reporter gene to facilitate identification and selection of expressing cells from a cell population seeking to be transfected or infected by a viral vector. In other aspects, selectable markers may be carried on a single DNA segment and used for co-transfection procedures. Both selectable markers and reporter genes may be flanked by appropriate regulatory sequences so that they can be expressed in host cells. Useful selectable markers include, for example, antibiotic resistance genes, such as neo and the like.

[0158] Reporter gene is used to identify the cells of potential transfection and to evaluate the functionality of regulatory sequences. Generally, reporter gene is following gene: it is not present in or is expressed by receptor organism or tissue, and it encodes polypeptide, and the expression of this polypeptide is clearly represented by some easily detectable properties such as enzymatic activity. After DNA has been introduced into receptor cells, the expression of reporter gene is measured at the appropriate time. Suitable reporter gene can include the gene encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase or green fluorescent protein. Suitable expression system is well known and can utilize known technology to prepare or obtain commercially. Generally, the construct with minimum 5 flanking regions showing the highest level of reporter gene expression is identified as promoter. Such promoter region can be connected to reporter gene and used to evaluate the ability of reagent regulating promoter-driven transcription.

[0159] Methods for introducing genes into cells and expressing genes into cells are known in the art. In the context of expression vectors, vectors can be easily introduced into host cells, such as mammalian, bacterial, yeast or insect cells, by any method known in the art. For example, expression vectors can be transferred into host cells by physical, chemical or biological means.

[0160] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for introducing polynucleotides into host cells is calcium phosphate transfection.

[0161] Biological methods for introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used methods for inserting genes into mammalian cells such as human cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc. See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.

[0162] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads; and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

[0163] In the case of using a non-viral delivery system, an exemplary delivery vehicle is a liposome. Consider using lipid preparations to introduce nucleic acid into a host cell (in vitro, ex vivo or in vivo). On the other hand, the nucleic acid can be associated with a lipid. Nucleic acids associated with lipids can be encapsulated in the aqueous interior of the liposome, dispersed in the lipid bilayer of the liposome, attached to the liposome through a connecting molecule associated with both the liposome and the oligonucleotide, trapped in the liposome, compounded with the liposome, dispersed in a solution comprising lipids, mixed with lipids, combined with lipids, included in lipids as a suspension, included in micelles or compounded with micelles, or otherwise associated with lipids. The lipids, lipid / DNA or lipid / expression vectors associated with the composition are not limited to any specific structure in the solution. For example, they can be present in a bilayer structure, as micelles or have a "collapsed (collapsed)" structure. They can also be simply dispersed in a solution, possibly forming aggregates of size or shape inhomogeneity. Lipid is a fatty substance, which can be a naturally occurring or synthetic lipid. For example, lipids include fat droplets that occur naturally in the cytoplasm as well as compounds that contain long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

[0164] In the case of using a non-viral delivery system, the invention is exemplarily accomplished using genome editing technology, such as CRISPR-Cas9, ZFN or TALEN.

[0165] In a preferred embodiment of the present invention, the vector is a lentiviral vector.

[0166] The DNA construct further comprises a signal peptide coding sequence. Preferably, the signal peptide sequence is connected upstream of the nucleic acid sequence of the antigen binding domain.

[0167] Therapeutic applications

[0168] The present invention includes cells transduced with a lentiviral vector (LV) encoding an expression cassette of the present invention. The transduced T cells can induce a CAR-mediated T cell response.

[0169] Therefore, the present invention also provides a method for stimulating a T cell-mediated immune response to a target cell population or tissue in a mammal, comprising the following steps: administering the CAR-T cell of the present invention to the mammal.

[0170] In one embodiment, the present invention includes a type of cell therapy in which T cells are genetically modified to express the CAR of the present invention, and the CAR-T cells are infused into a recipient in need. The infused cells are capable of killing tumor cells in the recipient. Unlike antibody therapy, CAR-T cells are able to replicate in vivo, resulting in long-term persistence that can lead to sustained tumor control.

[0171] In one embodiment, the CAR-T cells of the present invention can undergo robust in vivo T cell expansion and can sustain an extended amount of time. In addition, the CAR-mediated immune response can be part of an adoptive immunotherapy step, wherein the CAR-modified T cells induce an immune response specific to the antigen binding domain in the CAR.

[0172] Although the data disclosed herein specifically discloses lentiviral vectors comprising anti-CD19 scFv, anti-CD22 nanobodies, hinge and transmembrane regions, and ICOS, 4-1BB and CD3ζ signaling domains, the present invention should be construed to include any number of variations to each of the construct components.

[0173] Indicative diseases that can be treated include CD19 and / or CD22-related cancers or tumors, such as CD19 and / or CD22-positive tumors or cancers.

[0174] The CD19 and / or CD22-associated cancer or tumor may include a solid tumor, in particular hepatocellular carcinoma, melanoma, ovarian cancer, lung squamous cell carcinoma, gastric cancer, breast cancer, or a combination thereof.

[0175] The CD19 and / or CD22-related cancer or tumor may include a blood tumor, particularly a B-cell related tumor, including but not limited to: acute B-lymphocytic leukemia (B-ALL), B-cell lymphoma, or a combination thereof.

[0176] The cancer types treated with the CAR of the present invention include, but are not limited to, carcinoma, germ cell tumor and sarcoma, and certain benign and malignant tumors, and malignant tumors, such as sarcoma, carcinoma and melanoma. Also included are adult tumors / cancers and pediatric tumors / cancers.

[0177] Solid tumors are abnormal masses of tissue that usually do not contain cysts or fluid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named after the cell types that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumors such as sarcomas and carcinomas include fibrosarcomas, myxosarcoma, liposarcoma, mesothelioma, lymphoid malignancies, pancreatic cancer, ovarian cancer,.

[0178] The CAR-modified T cells of the present invention can also be used as a type of vaccine for ex vivo immunization and / or in vivo therapy of mammals. Preferably, the mammal is a human.

[0179] For ex vivo immunization, at least one of the following occurs in vitro prior to administering the cells into a mammal: i) expanding the cells, ii) introducing a nucleic acid encoding a CAR into the cells, and / or iii) cryopreserving the cells.

[0180] Ex vivo procedures are well known in the art and are discussed more fully below. Briefly, cells are isolated from mammals (preferably humans) and genetically modified (i.e., in vitro transduction or transfection) with vectors expressing CAR disclosed herein. CAR-modified cells can be administered to a mammalian recipient to provide therapeutic benefits. The mammalian recipient can be human, and the CAR-modified cells can be autologous relative to the recipient. Alternatively, the cells can be allogeneic, syngeneic, or xenogeneic relative to the recipient.

[0181] In addition to the use of cell-based vaccines for ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response against an antigen in a patient.

[0182] Typically, cells activated and amplified as described herein can be used to treat and prevent diseases produced in immunocompromised individuals. In particular, the CAR-modified T cells of the present invention are used for the treatment of B cell tumors, particularly relapsed refractory B cell tumors. In certain embodiments, the cells of the present invention are used to treat patients at risk of suffering from B cell tumors. Therefore, the present invention provides a method for treating or preventing B cell tumors, comprising administering a therapeutically effective amount of a CAR-modified T cell of the present invention to a subject in need.

[0183] The CAR-modified T cells of the present invention may be administered alone or as a pharmaceutical composition in combination with a diluent and / or with other components such as IL-2, IL-17 or other cytokines or cell groups. Simply put, the pharmaceutical composition of the present invention may include a target cell group as described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such a composition may include a buffer such as neutral buffered saline, sulfate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The composition of the present invention is preferably formulated for intravenous administration.

[0184] The pharmaceutical composition of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease-although the appropriate dosage can be determined by clinical trials.

[0185] When an "immunologically effective amount", "anti-tumor effective amount", "tumor-suppressive effective amount" or "therapeutic amount" is indicated, the exact amount of the composition of the present invention to be administered can be determined by a physician, who takes into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. It can be generally stated that the pharmaceutical composition comprising the T cells described herein can be administered in an amount of 10 4 Up to 10 9 The dosage is preferably 10 cells / kg body weight. 5 Up to 10 6 The T cell composition can also be administered at these doses multiple times. The cells can be administered by using well-known injection techniques in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988). The optimal dose and treatment regimen for a specific patient can be easily determined by a medical technician by monitoring the patient's disease signs and adjusting the treatment accordingly.

[0186] Administration of the subject composition can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The compositions described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranodally, intraspinal, intramuscularly, by intravenous (iv) injection or intraperitoneally. In one embodiment, the T cell composition of the present invention is administered to the patient by intradermal or subcutaneous injection. In another embodiment, the T cell composition of the present invention is preferably administered by iv injection. The composition of the T cell can be injected directly into the tumor, lymph node or infection site.

[0187] In certain embodiments of the invention, cells activated and expanded using the methods described herein or other methods known in the art to expand T cells to therapeutic levels are administered to patients in combination with any number of related treatment forms (e.g., before, simultaneously or after), including but not limited to treatment with the following agents: agents such as antiviral therapy, cidofovir and interleukin-2, cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efavirenz treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the present invention can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate and FK506, antibodies or other immunotherapeutic agents. In further embodiments, the cell compositions of the present invention are administered to patients in combination with bone marrow transplantation, using chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide (e.g., before, simultaneously or after). For example, in one embodiment, the subject can undergo standard treatment with high-dose chemotherapy followed by peripheral blood stem cell transplantation. In some embodiments, the subject receives an infusion of the expanded immune cells of the invention following transplantation. In an additional embodiment, the expanded cells are administered prior to or after surgery.

[0188] The dosage of the above treatments administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The dosage ratio for human administration can be implemented according to practices accepted in the art. Typically, 1×10 6 to 1×10 10 The modified T cells of the present invention are administered to the patient, for example, by intravenous infusion.

[0189] The main advantages of the present invention include:

[0190] (a) The anti-CD19 / CD22 bispecific CAR-T cells of the present invention can continuously kill tumors in vivo and have good therapeutic effects.

[0191] (b) The bispecific CAR-T cells of the present invention can produce more cytokines (such as IL-2, IFN-γ, etc.) than anti-CD19-CAR and anti-CD22-CAR alone. At the same time, the secretion of the immunosuppressive factor IL-10 is unexpectedly significantly reduced compared with CD22-CAR alone, which is less likely to cause immunosuppression while improving the lethality.

[0192] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0193] Materials and Methods

[0194] Construction of CAR-T cells

[0195] The structures of CD19 CAR, CD22 CAR and Bis-AD CAR are as follows Figure 1A and Figure 2A . Lentivirus stock solution was produced using 293T cells, and the collected virus supernatant was concentrated. Peripheral blood mononuclear cells (PBMC) from healthy donors were separated by Ficoll method, washed, cultured in TexMACSTMGMP medium supplemented with IL-7 and IL-15, and activated with Mitenyi Biotec human T cell activator CD3 / CD28 magnetic beads. After 2 days, the activated PBMCs were transduced with lentivirus concentrate. These cells were expanded for 7 days before quality testing.

[0196] In vitro functional testing of CAR-T cells

[0197] CAR-T cells were co-incubated with Raji, K562, and Nalm6 in 1640 medium for 24 or 48 hours. The culture supernatant was harvested and analyzed using a BD cytokine kit. Cells were centrifuged and collected to detect firefly luciferase activity or expression of apoptosis markers. In the antigen repeated stimulation experiment, 12 replicate wells were plated in parallel for each CAR-T, and Raji cells naturally expressing CD19 and CD22 were added at a 1:1 effector-target ratio every day, and cells from three wells were analyzed every day.

[0198] Flow cytometric analysis

[0199] CAR-T cells were washed with buffer and then incubated with Anti-human CD3 (BD ​​Biosciences), Anti-human CD45RA, Anti-human CD62L, Anti-human CD69, Anti-human CD25, Anti-humanTIM3, and Anti-human LAG3 antibody dilutions at 4°C in the dark for at least 30 min. The antibodies were then washed away and fluorescence was detected on a flow cytometer (Backman).

[0200] Animal experiments

[0201] For the study of the in vivo efficacy of CAR-T cells, 1×10 6 Raji-luciferase-GFP cells were injected into NOD-PrkdcscidIl2rgtm1 / Bcgen (NSG) mice through the tail vein. On the fourth day of tumor growth, 1×10 7 CAR-T cells were added. Bioluminescence imaging was performed using the IVIS imaging system (PerkinElmer) and Living Image software (PerkinElmer) to obtain imaging data. The body weight and survival of mice were continuously monitored.

[0202] Statistical analysis

[0203] Statistical analysis in this study was performed using Prism 8.0.1 (GraphPad) software. Comparisons between the two groups were performed using Student's t test. In each figure, ****p<0.0001; ***p<0.001; **p<0.01, *p<0.05. p<0.05 was considered statistically significant.

[0204] Example 1 Construction and functional verification of CD22-CAR-T cells based on nanobody sequences

[0205] The CD22 single-target CAR structure was designed using the CD22 nanobody sequence ( Figure 1A ). CD22 CAR-T cells were constructed by lentiviral transfection. The results of in vitro killing experiments showed that CD22 CAR-T cells have specific cytotoxicity and cytokine release against target cells ( Figure 1B -D). The results of in vivo experiments showed that compared with the control group, CD22 CAR-T cells had a certain degree of clearance effect on tumor cells in mice and significantly prolonged the survival of mice ( Figure 1E -H). This indicates that CD22 CAR-T cells have a certain anti-tumor effect.

[0206] Next, CD19 / CD22 bispecific Bis-A CAR-T cells were constructed, and their structure is as follows Figure 2A As shown. Bis-A CAR, CD19 CAR, and CD22 CAR were packaged with lentivirus at the same time, and CAR-T cells were prepared by transfection. These three CAR-T cells were co-incubated with Raji cells under different effector-target ratios, and the apoptosis of tumor cells was detected after 24 hours.

[0207] Results: CD19 CAR-T cells showed significant killing effects on target cells under different effector-target ratios. On the contrary, the cytotoxicity of Bis-A CAR-T cells to tumor cells was not as good as that of CAR-T cells alone ( Fig. 1I -J). This result may be due to the conflict between the two antibody sequences when they bind to the tumor antigens when the dual-target CAR-T cells encounter tumor antigens, resulting in a decrease in the efficiency of binding between one sequence and the antigen, thus making the anti-tumor effect of the dual-target CAR-T cells inferior to that of CD19 CAR-T.

[0208] Therefore, in the following examples, the dual-target CAR-T cell structure was further optimized to observe whether the structural changes could further enhance the anti-tumor effect.

[0209] Example 2 Structural design and optimization of bispecific CAR vector

[0210] In this example, two linkers (G4S)4 and (EAAAK)3 were selected, and a total of four CD19 / CD22 dual-target CAR structures were designed. These four CAR structures are called BisA-D CAR ( Figure 2A ). Then, these four CAR structures were used to prepare CAR-T cells by lentiviral transfection. All four CARs can be stably expressed on T cells ( Figure 2B ). Then, these four dual-target CAR-T cells and two single-target CAR-T cells were co-incubated with Raji-luciferase cells at different effector-target ratios, and the fluorescence value of Raji-luciferase cells was detected by firefly luciferase method.

[0211] Compared with Bis-A CAR-T and Bis-B CAR-T, Bis-CCAR-T and Bis-D CAR-T cells using (EAAAK)3 as a linker showed more prominent cytotoxic effects on target cells. The detection results of cytokines in the supernatant of co-incubation also showed that Bis-C CAR-T and Bis-D CAR-T cells had higher levels of cytokine release ( Figure 2C -D).

[0212] A large number of studies have shown that IL-10 has the anti-tumor function of inhibiting adoptively transferred T cells. The results of this example show that the release level of IL-10 in Bis-C CAR-T and Bis-D CAR-T cells is unexpectedly significantly lower than that in CD22 CAR-T. In addition, it was also found that the release level of granzyme B was positively correlated with the killing results of CAR-T, indicating that the action of granzyme + perforin is the main mode of action of CAR-T cells to kill target cells.

[0213] Then, flow cytometry was used to detect the apoptosis of tumor cells after Bis-C CAR-T was co-cultured with Raji and Nalm6 cells. The results showed that the bispecific CAR-T cells with (EAAAK)3 as the linker had a cytotoxic effect on B cell tumor cell lines that was not weaker than that of the single-target CD19 CAR-T ( Figure 2E -F). Next, in order to detect the specificity of single-target CAR-T and dual-target CAR-T for their target antigens, three overexpression cell lines, CD19-K562, CD22-K562 and CD19 / CD22-K562, were constructed using CD19 and CD22 negative K562 cell lines. The experimental results showed that the four CAR-T cells only produced specific cytotoxicity to cell lines containing their target antigens and produced specific cytokine secretion.

[0214] In addition, according to Figure 2G The cell killing results shown and Figure 5 The cytokine secretion results shown in the figure unexpectedly found that Bis-C CAR-T and Bis-D CAR-T not only have similar cytotoxicity to their single-target target cells and dual-target target cells, but their killing ability and secretion of certain cytokines (such as IL-2) in single-target cells are even better than those of the corresponding monospecific CAR-T cells, indicating that the constructed Bis-CCAR-T and Bis-D CAR-T can produce sufficiently strong cytotoxicity to target cells with only one target, thereby better solving the problem of recurrence caused by the loss of a single target in clinical practice.

[0215] Example 3 Bispecific CAR-T cells have good sustained killing ability against target cells in vitro

[0216] In this example, the cell functions of Bis-C CAR-T and Bis-D CAR-T were further tested. CAR-T cells were co-incubated with tumor cells for 24 hours, and the activation markers on their cell surfaces were detected by flow cytometry. The results showed that after bispecific CAR-T cells were stimulated by CD19 or CD22 positive cell lines, the expression of CD69 and CD25 on their surfaces increased, indicating that both antigen positive cell lines can activate bispecific CAR-T cells, while the two single target CAR-T cannot be activated by the other antigen ( Figure 3A -B). The results of Example 2 showed that Bis-C CAR-T and Bis-D CAR-T had similar cytotoxicity in a single killing experiment in vitro. Next, an in vitro antigen repeated stimulation experiment was performed to simulate the long-term tumor antigen stimulation environment in vivo to explore the sustained killing ability of Bis-C CAR-T and Bis-D CAR-T. By adding tumor cells every day, the killing ability of these CAR-T cells was tested for four consecutive days, and the memory phenotype of CAR-T cells was tested.

[0217] The results showed that Bis-C CAR-T cells have a more excellent sustained killing ability ( Figure 3C ) and sustained release of IFN-γ and granzyme B ( Figure 3D At the same time, during the continuous killing process, Bis-CCAR-T cells gradually differentiate into the phenotypes of central memory T cells and effector memory T cells ( Figure 3E ). And after sustained killing, there is a relatively lower level of expression of exhaustion markers ( Figure 3F ).

[0218] Example 4 Bis-C CAR-T cells have excellent anti-tumor effects in vivo

[0219] Subsequently, CD19-K562 (CD19 overexpressing cell line) and CD22-K562 (CD22 overexpressing cell line) cells were mixed in different proportions to simulate negative recurrent tumor cells in patients after CD19 CAR-T treatment. The results of in vitro killing experiments showed that bispecific CAR-T cells had good killing effects on the two K562 mixed in different proportions, while the killing effects of the two single-target CAR-T cells depended on the proportion of cells positive for their specific antigens ( Figure 4A -B). Moreover, regardless of the mixing ratio, the killing performance of Bis-C CAR-T is always better than that of single-specific CD19-CAR and CD22-CAR.

[0220] Subsequently, a mouse relapse model was designed to evaluate the in vivo efficacy of Bis-C CAR-T and CD19 CAR-T on 100% Raji, 50% Raji + 50% CD19KO Raji, and 100% CD19KO Raji. The results showed that compared with the single-target CD19 CAR-T, Bis-C CAR-T could significantly control the growth of tumors in the 50% Raji + 50% CD19KO Raji and 100% CD19KO Raji groups of mice, while CD19 CAR-T was basically unable to inhibit the growth of tumors in the 50% Raji + 50% CD19KO Raji and 100% CD19KO Raji groups of mice. In addition, according to the statistical results of the survival curve, in all different target cell groups, Bis-C CAR-T can prolong the survival period by at least 7 days compared with CD19 CAR-T ( Figure 4C -G).

[0221] discuss

[0222] In the present invention, when designing bispecific CAR-T, the CD19 antibody sequence was first humanized, and CD22 nano antibodies were developed at the same time. Nano antibodies have the advantages of small size and high affinity. Bispecific CAR-T cells were constructed using CD19 humanized antibodies and CD22 nano antibodies. However, when the constructed CD19 / CD22 CAR-T cells were tested, it was found that their in vitro killing effect and cytokine secretion levels were not as good as the traditional CD19 CAR-T structure. It may be necessary to further optimize the structure of the bispecific CAR-T to truly reflect the effects of the two different antibody sequences it carries.

[0223] The present invention has modified its structure from two aspects. On the one hand, two different linkers were selected for comparison, and on the other hand, the order of the two antibody sequences was swapped. At the same time, during the design, attention was paid to avoiding the artificial svFv structure formed by the head-to-tail connection of the light and heavy chains of the two antibody sequences. Finally, four CD19 / CD22 dual-target CAR-T structures were constructed.

[0224] By testing the in vitro killing effects and cytokine secretion levels of these four CAR-Ts, it was found that the two structures using (EAAAK)3 as the linker had more significant cytotoxic effects and cytokine secretion levels. The reason may be that compared with the flexible and random coil conformation of the (G4S)4 linker, the stable (EAAAK)3 can more effectively separate the two connected antibody sequences, thereby not affecting their respective antigen binding functions.

[0225] Compared with the linker, the order of antibody sequence arrangement has less effect in the bispecific CAR structure. In the comparison of Bis-C CAR-T and Bis-D CAR-T, there was no significant difference in the single killing effect and cytokine secretion level between the two. Only in the process of sustained killing, Bis-C CAR-T cells showed a better sustained killing ability. At the same time, compared with CD19 CAR-T and CD22 CAR-T, Bis-C CAR-T has more significant cytotoxic effect and cytokine secretion. Because Bis-C CAR-T cells have an additional target for B cell malignant tumor cells, this cytotoxic effect is more specific. During repeated antigen stimulation, Bis-C CAR-T cells were detected to gradually differentiate into central memory T cells and effector memory T cells, and at the same time, they had lower levels of exhaustion marker expression. In an in vivo experiment simulating CD19-negative relapse, Bis-C CAR-T was better able to control tumor progression in mice in the group with low or no CD19 expression than CD19 CAR-T.

[0226] Sequence Listing

[0227]

[0228]

[0229]

[0230]

[0231] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A chimeric antigen receptor (CAR), characterized in that The chimeric antigen receptor has a structure shown in the following formula I from N-terminus to C-terminus: S-AB1-L-AB2-H-TM-C-CD3ζ(I) In the formula, Each "-" is independently a connecting peptide or a peptide bond; S is an optional signal peptide sequence; L is the connector; H is an optional hinge region; TM is the transmembrane domain; C is a co-stimulatory signal molecule; CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ; One of AB1 and AB2 is an antigen-binding domain targeting CD19, and the other is an antigen-binding domain targeting CD22.

2. The chimeric antigen receptor according to claim 1, wherein The antigen binding domain targeting CD22 is a nanobody having the following complementary determining regions CDR: CDR1 shown in SEQ ID NO: 1; CDR2 shown in SEQ ID NO:2; and CDR3 shown in SEQ ID NO:

3.

3. The chimeric antigen receptor according to claim 2, wherein The amino acid sequence of the CD22-targeting Nanobody is shown in SEQ ID NO:

4.

4. The chimeric antigen receptor according to claim 1, wherein The antigen binding domain targeting CD19 is a scFv, which has a heavy chain variable region and a light chain variable region, and the heavy chain variable region has the following complementary determining regions CDR: HCDR1 shown in SEQ ID NO:5; HCDR2 shown in SEQ ID NO:6; and HCDR3 shown in SEQ ID NO:7; The light chain variable region has the following complementarity determining regions CDR: LCDR1 shown in SEQ ID NO:8; LCDR2 shown in SEQ ID NO:9; LCDR3 shown in SEQ ID NO:

10.

5. The chimeric antigen receptor according to claim 4, wherein The CD19-targeting scFv has a heavy chain variable region as shown in SEQ ID NO: 11 and / or a light chain variable region as shown in SEQ ID NO:

12.

6. The chimeric antigen receptor according to claim 1, wherein The joint L is a rigid joint.

7. The chimeric antigen receptor according to claim 1, wherein The CAR amino acid sequence is shown in SEQ ID NO: 23, 24, 25 or 26.

8. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the chimeric antigen receptor (CAR) as described in claim 1.

9. A carrier, characterized in that The vector contains the nucleic acid molecule as claimed in claim 2.

10. An engineered immune cell, characterized in that: The immune cells express the CAR as described in claim 1.

Citation Information

Patent Citations

  • Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof

    US5350674A

  • Gene therapy

    US5399346A

  • Delivery of exogenous DNA sequences in a mammal

    US5580859A

  • Adenovirus vectors for gene therapy

    US5585362A

  • Induction of a protective immune response in a mammal by injecting a DNA sequence

    US5589466A